Theravance Biopharma, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
Assets
Current assets:
Cash and cash equivalents
Short-term marketable securities
Receivables from collaborative arrangements
Amounts due from TRC, LLC
Receivables from milestones and royalty assets
Prepaid clinical and development services
Other prepaid and current assets
Amounts due from TRC, LLC (Discontinued operations)
Total current assets

Long-term marketable securities
Property and equipment, net
Operating lease assets
Equity in net assets of TRC, LLC
Future contingent milestone and royalty assets
Restricted cash
Other assets
Equity in net assets of TRC, LLC (Discontinued operations)
Total assets

Liabilities and Equity
Current liabilities:
Accounts payable
Accrued personnel-related expenses
Accrued clinical and development expenses
Accrued general and administrative expenses
Operating lease liabilities
Deferred revenue
Current portion of non-recourse notes due 2035, net
Income tax payable
Other accrued liabilities
Income tax payable (Discontinued operations)
Accrued interest payable
Current portion of non-recourse notes due 2035, net (Discontinued operations)
Accrued interest payable (Discontinued operations)
Tenant improvement payable to sublessee
Total current liabilities

Long-term operating lease liabilities
Future royalty payment contingency
Long-term deferred revenue
Unrecognized tax benefits
Other long-term liabilities
Convertible senior notes due 2023, net
Non-recourse notes due 2035, net
Shareholders' Equity
Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 51,891 and 51,069 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total shareholders' equity
Total liabilities and shareholders' equity

Comments